Weight Loss in Parkinson’s Disease: The Relationship with Motor Symptoms and Disease Progression

Table 2

Prevalence of weight loss among patients with motor complications and receiving dopaminergic therapies.

Motor complications /; dopaminergic therapies	WL
	Yes	No
	n (%)	n (%)	p value
Wearing Off (n= 91)	55 (60.4)	36 (39.6)	< 0.001
DK (n= 63)	41 (65.1)	22 (34.9)	<0.001
FOG (n= 49)	34 (69.4)	15 (30.6)	< 0.001
Levodopa (n=110)	61 (55.5)	49 (44.5)	0.003
DA (n= 91)	48 (52.7)	43 (47.3)	ns

PD= Parkinson’s disease; WL= weight loss; DK= dyskinesias; DA= dopamine agonists; ns= not significant; n= number of cases